HIV-1(89.6) Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in mice.
We have constructed a replication competent, gamma(1)34.5-deleted herpes simplex virus type-1 (HSV-1) vector (J200) that expresses the gag gene from human immunodeficiency virus type-1, primary isolate 89.6 (HIV-1(89.6)), as a candidate vaccine for HIV-1. J200 replicates in vitro, resulting in abundant Gag protein production and accumulation in the extracellular media. Immunization of Balb/c mice with a single intraperitoneal injection of J200 elicited strong Gag-specific CD8 responses, as measured by intracellular IFN-gamma staining and flow cytometry analysis. Responses were highest between 6 weeks and 4 months, but persisted at 9 months post-immunization, the last time-point evaluated. These data highlight the potential utility of neuroattenuated, replication competent HSV-1 vectors for delivery of HIV-1 immunogens.
Parker
Scott D
SD
Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL 35294, United States.
Rottinghaus
Scott T
ST
Zajac
Allan J
AJ
Yue
Ling
L
Hunter
Eric
E
Whitley
Richard J
RJ
Parker
Jacqueline N
JN
D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002460:Cell Line; D002522:Chlorocebus aethiops; D005260:Female; D015967:Gene Expression Regulation, Viral; D015683:Gene Products, gag / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D005822:Genetic Vectors / Q000235:genetics*; D015497:HIV-1 / Q000502:physiology*; D007114:Immunization; D051379:Mice; D008807:Mice, Inbred BALB C; D014779:Virus Replication
D015683:Gene Products, gag
Gene Ther. 1998 Jun;5(6):809-19
9747461
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4512-7
10200293
J Virol. 1999 Nov;73(11):9145-52
10516021
Gene Ther. 1999 Oct;6(10):1751-8
10516725
J Virol. 2004 Dec;78(24):13455-9
15564456
Sex Transm Dis. 2004 Dec;31(12):753-60
15608591
J Virol. 2005 Feb;79(4):2124-32
15681415
J Infect Dis. 2005 Mar 1;191(5):654-65
15688278
J Infect Dis. 2005 Mar 1;191(5):666-77
15688279
J Virol. 2005 Mar;79(6):3243-53
15731219
J Virol. 2005 Jun;79(11):7135-45
15890953
J Infect Dis. 2001 May 1;183(9):1343-52
11294665
J Virol. 2001 Sep;75(18):8724-32
11507217
J Virol. 2001 Dec;75(23):11821-6
11689663
Expert Opin Biol Ther. 2001 Mar;1(2):177-91
11727528
J Immunol. 2002 Jan 1;168(1):332-7
11751978
Nature. 2002 Jan 17;415(6869):331-5
11797011
AIDS. 2001;15 Suppl 5:S147-58
11816163
Annu Rev Immunol. 2002;20:73-99
11861598
J Virol. 2002 Apr;76(8):3678-87
11907207
J Biomed Sci. 2002 Mar-Apr;9(2):100-11
11914576
Gene Ther. 2002 Mar;9(6):398-406
11960316
J Virol. 2002 Jun;76(11):5565-80
11991985
J Virol. 2003 Jun;77(11):6305-13
12743287
J Virol. 2004 Mar;78(5):2212-21
14963117
J Virol. 2004 Apr;78(7):3333-42
15016855
Gene Ther. 2000 May;7(10):859-66
10845724
Gene Ther. 2000 May;7(10):867-74
10845725
J Virol. 2000 Sep;74(17):7745-54
10933680
J Virol. 2001 May;75(9):4430-4
11287595
Science. 2001 Apr 6;292(5514):69-74
11393868
J Clin Invest. 1993 Jun;91(6):2837-43
8390490
Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1256-60
8108397
J Virol. 1994 Jul;68(7):4650-5
8207839
J Virol. 1994 Sep;68(9):6103-10
8057491
J Gen Virol. 1995 Feb;76 ( Pt 2):321-32
7844554
J Virol. 1995 Jun;69(6):3615-23
7745709
Science. 1998 Mar 27;279(5359):2103-6
9516110
Gene Ther. 1998 Jan;5(1):121-30
9536273
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8216-21
9653167
J Virol. 1998 Oct;72(10):8264-72
9733870
J Gen Virol. 2004 Apr;85(Pt 4):911-9
15039533
J Virol. 2004 Apr;78(8):3930-40
15047809
J Exp Med. 2004 Jun 21;199(12):1709-18
15210746
J Clin Invest. 2004 Aug;114(4):450-62
15314679
Gene Ther. 2004 Nov;11(22):1648-58
15334111
Cell. 1981 Jul;25(1):227-32
6268303
Proc Natl Acad Sci U S A. 1984 Sep;81(18):5867-70
6091116
J Virol. 1986 Aug;59(2):494-9
3016310
Mol Cell Biol. 1985 Dec;5(12):3403-9
3939316
Proc Natl Acad Sci U S A. 1988 Jul;85(14):5200-4
2455898
Nature. 1990 Jun 14;345(6276):622-5
2190095
Science. 1990 Nov 30;250(4985):1262-6
2173860
Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):542-6
1988952
Science. 1991 May 10;252(5007):854-6
1851332
J Virol. 1992 Jul;66(7):4464-9
1602554
Curr Drug Targets Infect Disord. 2005 Jun;5(2):81-3
15975014
J Gen Virol. 2005 Sep;86(Pt 9):2401-10
16099897
J Infect Dis. 2005 Oct 1;192(7):1249-59
16136469
Virology. 2005 Oct 25;341(2):190-202
16098555
Vaccine. 2006 Jan 23;24(4):417-25
16176847
J Immunol. 2006 May 15;176(10):6130-46
16670322
Vaccine. 2006 May 22;24(21):4498-502
16185790
Virology. 2007 Jan 20;357(2):199-214
16962628
Virology. 2007 Jan 20;357(2):186-98
16996101
Vaccine. 2007 Feb 19;25(9):1634-46
17145123
J Virol. 1992 Dec;66(12):7517-21
1433527
Cancer Gene Ther. 2000 Jan;7(1):118-27
10678364
Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2208-13
10681459